Latest Breaking News On - Geoffrey mogilner - Page 6 : comparemela.com

Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress

Oral presentation by Dr. Nancy U. Lin from Dana-Farber Cancer Institute at 8:55 a.m. CEST/2:55 a.m. ET on October 22, 2023Olema will host an investor conference call at 8:00 a.m. ET on October 23,.

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

Olema Oncology Announces Expansion of Collaboration Agreement with Novartis

Amended clinical collaboration and supply agreement increases the palazestrant/ribociclib combination Phase 1/2 clinical study size to approximately 60 patients Expanded study supports the potential.

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Olema Pharmaceuticals (NASDAQ:OLMA)

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and

Olema Oncology to Participate in Upcoming Investor

SAN FRANCISCO, Sept. 06, 2023 (GLOBE NEWSWIRE) Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage.